Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors question trial protocols and transparency as Novo plans a new study.

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

Both Novo Nordisk and Eli Lilly's current weight loss treatments are administered via injection ... including its hotly anticipated experimental CagriSema treatment. Late-stage CagriSema trial ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new ... she experiences in the 24 hours after her weekly CagriSema injection are so bad that she sometimes can't leave ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from ... fog she experiences in the 24 hours after her weekly CagriSema injection are so bad that she sometimes can't leave bed.

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk (NVO ... Novo believes CagriSema could be more powerful than its blockbuster weight-loss injection Wegovy, but investors are worried whether it ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk is under pressure from ... she experiences in the 24 hours after her weekly CagriSema injection are so bad that she sometimes can't leave ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors ... hammered its shares in December. Novo believes CagriSema could be more powerful than its blockbuster weight-loss ...